Cardioprotective effects of GLP-1 assessed by conductance catheter
Research type
Research Study
Full title
Investigation into Cardioprotective effect of Glucagon-like Peptide-1 and its mechanism of action during myocardial ischaemia assessed during percutaneous coronary intervention by conductance catheter
IRAS ID
145182
Contact name
Stephen Hoole
Contact email
Sponsor organisation
Papworth Hospital NHS Foundation Trust
Research summary
Ischaemic heart disease is the most common cause of death in the UK. Glucagon-like peptide-1 (GLP-1) has been demonstrated to protect the heart when it is deprived of blood supply (ischaemia). The mechanism for this protection is not clear. Similar protection occurs with ischaemic conditioning of the heart, which is dependent on potassium channel opening.
We intend to establish whether GLP-1 mediated protection shares a similar mechanistic pathway. In order to do this we will measures pressure-volume loops generated in the main pumping chamber of the heart at the time of a percutaneous coronary intervention (stenting). Patients will be randomised to GLP-1 alone, GLP-1 with glibenclamide (a potassium channel blocking medication approved for human use) or glibenclamide alone.
REC name
East of England - Cambridge East Research Ethics Committee
REC reference
14/EE/0056
Date of REC Opinion
2 Apr 2014
REC opinion
Further Information Favourable Opinion